Log in or Sign up for Free to view tailored content for your specialty!
Diabetes Education News
VIDEO: Diabetes technology access affected by disparities in 'digital connectivity'
Healio spoke with David Klonoff, MD, about disparities in access to diabetes technology.
VIDEO: Diabetes technology and telemedicine are 'made for each other'
Healio spoke with David Klonoff, MD, about how increasing use of telemedicine has impacted diabetes technology.
Log in or Sign up for Free to view tailored content for your specialty!
VIDEO: Exploring new devices, options to measure glucose for diabetes
Healio spoke with David Klonoff, MD, about recently developed devices in diabetes technology.
VIDEO: Using patient information, data in diabetes care
Healio spoke with David Klonoff, MD, about recent advancements using available data in diabetes technology.
VIDEO: Recent developments in sensors for diabetes monitoring
Healio spoke with David Klonoff, MD, about recent advancements in sensors in the field of diabetes technology.
VIDEO: Medication advancements impacted by diabetes technology innovations
Healio spoke with David Klonoff, MD, about the latest innovations in diabetes medications.
Patients with diabetes, worsening HF benefit from sotagliflozin at or before discharge
In a post hoc analysis of SOLOIST-WHF, patients with type 2 diabetes hospitalized for worsening HF had lower rates of CV death and HF rehospitalization if they received sotagliflozin on or before discharge than if they did not.
Toothbrushing twice daily may be linked to better glucose levels in type 2 diabetes
HOUSTON — Toothbrushing two times per day may improve glycemic control for people with type 2 diabetes, but more studies on the link between oral health and type 2 diabetes are needed, according to presenters.
VIDEO: Tips for keeping children with type 1 diabetes safe at school
SAN DIEGO — In this video exclusive, Anastasia Albanese-O’Neill, PhD, APRN, RN, CDCES, discusses important resources for schools to better care for children with type 1 diabetes.
Topline data show semaglutide cuts CV risk by 20%: SELECT
Compared with placebo, injectable semaglutide 2.4 mg reduced risk for major adverse CV events by 20% for people with overweight or obesity and established CVD, according to topline data from the SELECT study.
-
Headline News
‘Truly alarming’: Life expectancy gap in the US now up to 20 years
November 22, 20243 min read -
Headline News
Autoantibodies present in long COVID, but not a ‘smoking gun’ for new autoimmune disease
November 25, 20242 min read -
Headline News
Cardiovascular disease deaths rising among younger adults living in rural areas
November 15, 20243 min read
-
Headline News
‘Truly alarming’: Life expectancy gap in the US now up to 20 years
November 22, 20243 min read -
Headline News
Autoantibodies present in long COVID, but not a ‘smoking gun’ for new autoimmune disease
November 25, 20242 min read -
Headline News
Cardiovascular disease deaths rising among younger adults living in rural areas
November 15, 20243 min read